Hesperos, Inc. (HESP)
Hesperos will go public soon, but the exact IPO date is still unknown.
Stock Price: Pending
IPO price not available yet

Company Description

Hesperos, Inc. is a socially-conscious company that uses our non-invasive, serum-free, multi-organ chip platform (Human-on-a-Chip) systems to provide pre-clinical analytical services with the goal of accelerating drug discovery and general toxicology testing and reducing use of animal testing.

Our Human-on-a-Chip platform system mimics the process of initial patient evaluation during a clinical trial, where functional human in vitro tissues are evaluated similar to a patient undergoing medical testing to determine baseline performance metrics.

Specific screens for heart rate, respiration, basic cognitive function, reflex tests on muscle and nerve, elimination, and chemical screens for liver, kidney and hematopoietic function can be integrated into our unique pumpless platform.

If anything abnormal is observed, additional biomarkers are evaluated much like a blood test administered to a patient.

If a chip ceases to function, a “post mortem” examination of the tissue is completed. This approach enables the platform to be utilized not only for acute but also chronic evaluation of drugs non-invasively for periods of up to several months depending on the system.

Because of our holistic approach to the process of pre-clinical evaluation, more subtle effects, not just cell death, can be detected in our system.

This use of functional readouts reduces the number and frequency of biomarker assays which reduces costs and increases efficiency during pre-clinical evaluations.

Our platform can target rare diseases (of the over 7,000 known rare diseases, approximately 95 percent have no treatment because of a lack of animal models).

We have licensed patents from Cornell University and the University of Central Florida to support our systems.

We have successfully completed projects with 15 commercial clients, including Roche, AstraZeneca, L’Oreal, Sanofi and several others, the results of which are detailed in high impact journals.

The Sanofi project provided efficacy data for an investigational new drug application to the FDA which enabled the authorization of a clinical trial.

Hesperos, Inc.
Country United States
Founded 2015
Industry Health Care
Sector Life Sciences Tools & Services
Employees 27
CEO James F. Kronauge, Jr., Ph.D.

Contact Details

Address:
12501 Research Parkway Suite 100
Orlando, FL 32826
United States
Phone (407) 900-5915
Website hesperosinc.com

Stock Details

Ticker Symbol HESP
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001907702
Employer ID 47-2107365
SIC Code 8731

Key Executives

Name Position
James F. Kronauge, Jr., Ph.D. Chief Executive Officer
Kenneth D. Najour, DBA, CPA Chief Financial Officer
Michael L. Shuler, Ph.D. President and Director
James J. Hickman, Ph.D. Chief Scientist and Chairman of the Board
Gilberto M. Villacorta, Ph.D. Vice President and Secretary
Antonio Marra, Jr. Director
James Stanker Director
Kathryn O’Connor Gardner Director

Latest SEC Filings

Date Type Title
Aug 9, 2024 S-1/A [Amend] General form for registration of securities under the Securities Act of 1933
Aug 14, 2023 S-1/A [Amend] General form for registration of securities under the Securities Act of 1933
Jul 13, 2022 S-1 General form for registration of securities under the Securities Act of 1933
May 16, 2022 DRS/A [Amend] [Cover] Draft Registration Statement
Feb 14, 2022 DRS [Cover] Draft Registration Statement